A recent trend to incorporate patient-reported outcomes (PROs) in clinical research, and ultimately clinical practice, is a response to the need to better measure and treat what patients truly care about, and adapt to the changing healthcare environment, which increasingly includes patient satisfaction as a key metric for overall quality of care, a metric tied…
NEW YORK (Reuters Health)—Sleep apnea may increase the risk of developing gout and experiencing flare-ups, according to a new study. Until now, little was known about the relationship between the two conditions, the study team writes in an article online Oct. 19 in Arthritis & Rheumatology. Obesity plays an important role in both sleep apnea…
Dietary triggers of gout flares are associated with high levels of serum urate. A study recently uncovered an association between high serum urate and tomatoes, the first such link established beyond patient anecdotes…
A new data-driven study tracked and analyzed gout-related healthcare costs for more than three years, determining the financial burden of flares and the possible benefit of proper flare management…
New research by physicists from Johns Hopkins University explores the correlation between the sun’s geomagnetic activity and the incidence of giant cell arteritis and rheumatoid arthritis, including geographic latitudes that put residents at highest risk.
New research published in May indicates a possible connection between B cells and the occurrence of systemic lupus erythematosus symptoms.
In addition to the impediments to consistent, high-quality care suffered by all incarcerated individuals, incarcerated patients with rheumatic disease face challenges specific to the treatment, management & monitoring of rheumatic conditions.
“Doctor, I hate to tell you this but that shelf is definitely not made of wood,” my patient gently chided me as I knocked on a plastic piece of shelving. “I know … but you get the point,” I replied with a small laugh. It’s become a habit of mine over the past few years…
In summer 2024, two phase 3 studies were released with promising findings for the treatment of patients with systemic lupus erythematosus (SLE) and those with lupus nephritis. SLE Disease Activity Dapirolizumab pegol is a novel, investigational, Fc-free anti-CD40L agent for people living with moderate to severe SLE.1 The randomized, double-blind, parallel-group PHOENYCS GO trial (N=321)…
In late July 2022, the U.S. Food & Drug Administration (FDA) approved belimumab (Benlysta) for the treatment of children with active lupus nephritis aged 5 to 17 years old receiving standard therapy.1 Despite recent advances in treatment options for patients with systemic lupus erythematosus (SLE), those with kidney involvement may develop endstage renal disease and…